Clinical trial NCT02992951: DACC in the REduction of Surgical Site INfection
Official title: A Randomised Controlled Trial to Assess the Clinical and Cost Effectiveness of Dialkylcarbamoylchloride (DACC) Coated Post-operative Dressings Versus Standard Care in the Prevention of Surgical Site Infection in Clean or Clean-contaminated, Vascular Surgery.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Infection, Bacterial
Wound Infection
Wound Infection, Surgical
Surgical Incision
Surgical Wound
Keywords: Infection
Surgical Site Infection
Dialkylcarbamoylchloride
Lead sponsor: Hull University Teaching Hospitals NHS Trust
Sponsor class: OTHER_GOV
Collaborators: name: University of Hull
First posted: 2016-12-14
Enrollment: 718
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Surgical site infection is an infection at a place in the body where surgery has taken place, and has been reported in around 5% of people undergoing an operation. In vascular surgery, infection rates are as high as 30%. Methods to reduce this rate of infection should be investigated thoroughly for their effectiveness and cost-effectiveness.

The investigators aim to conduct a research trial examining one such method. Leukomed Sorbact is a wound dressing coated with a chemical (DACC) derived from spider-silk that interacts with, and binds bacteria, causing them to be mechanically removed from a wound when the dressing is changed. The trial aims to compare the effectiveness of this dressing to a standard, non-coated dressing, in the reduction of surgical site infection.

718 patients from a number of centres across the UK will be recruited to this study. Adult patients who are having a vascular surgery operation will be approached for entry into the trial. The trial will be explained to them, as well as an explanation that participation is voluntary and their operation or other aspects of their care will not be impacted in any way should participants not wish to participate.

Participants will be randomised by computer into one of two groups - one group whose wounds are dressed with Leukomed Sorbact, and the other whose wounds are dressed with a standard dressing. Patients will be followed up at 30 days post-operatively. At the follow up, their wounds will be inspected for infection, and participants will be asked to complete short questionnaires measuring quality of life. Quality of life will also be assessed at 3 months post surgery.

The trial will aim to answer a number of questions, with the primary question being does a DACC coated dressing applied after an operation reduce the risk of an infection at the surgery site? It will also ask whether this treatment is cost-effective and whether it promotes satisfactory healing and evaluate the overall carbon footprint impact of each intervention.

Studies Within a Trial will be conducted to validate a remote diagnostic measure for detecting surgical site infection using wound images and the Bluebelle Wound Healing Questionnaire, evaluate feasibility of novel hair removal methods such as epilation and waxing, carbon footprint modelling within randomised controlled trials.


Eligibility criteria: Inclusion Criteria:

In order to be eligible for inclusion in the study the participants must meet the following criteria:

* Adults ≥18 yrs undergoing clean or clean-contaminated lower limb vascular surgery, with wounds closed by primary intention.
* Able to understand the Patient Information Sheet and supplementary materials and capable and willing to give informed consent and follow the protocol requirements (including attending all follow-up visits and completing written questionnaires).

Exclusion Criteria:

Patients will not be included in the study if they meet any of the following exclusion criteria:

* Patients on antibiotics for other conditions at the time of surgery or in the follow up period.
* Patients undergoing any procedure that does not include lower limb incisions.
* Allergies to any component of either the DACC-coated dressing or the control dressing.
* Inability to give informed consent due to incapacity (as defined by the MCA 2005)
* Aged under 18 years at the time of recruitment
* Use of investigational drug/device therapy within preceding 4 weeks that may interfere with this study.

Primary outcomes:
measure: 30 day infection rate
timeFrame: 30 days
Secondary outcomes:
measure: 3 month infection rate
timeFrame: 3 months
measure: Quality of Life (SF-36 V2)
timeFrame: 30 days, 3 months
measure: Quality of Life (EQ-5D-3L)
timeFrame: 30 days, 3 months
measure: Mortality
timeFrame: 30 days
measure: Bluebelle wound healing questionnaire
timeFrame: Days 30 and 37
measure: Carbon Footprint Analysis
timeFrame: 3 months
Other outcomes:
measure: SWAT 1 Validation Acceptability
timeFrame: 30 and 37 days
measure: SWAT 1 Validation reliability
timeFrame: 30 and 37 days
measure: SWAT 1 Validation Validity
timeFrame: 30 days
measure: SWAT 2 Hair Removal Feasibility
timeFrame: 30 days
measure: Carbon Footprint Model Development
timeFrame: 3 months
Locations:
city: Hull
country: United Kingdom
facility: Academic Vascular Surgery Unit, Vascular Laboratory, Alderson House, Hull Royal Infirmary
state: East Riding Of Yorkshire
Study officials:
affiliation: Hull University Teaching Hospitals NHS Trust
name: George Smith, M.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Totty JP, Harwood AE, Cai PL, Hitchman LH, Smith GE, Chetter IC. Assessing the effectiveness of dialkylcarbamoylchloride (DACC)-coated post-operative dressings versus standard care in the prevention of surgical site infection in clean or clean-contaminated, vascular surgery (the DRESSINg trial): study protocol for a pilot feasibility randomised controlled trial. Pilot Feasibility Stud. 2019 Jan 18;5:11. doi: 10.1186/s40814-019-0400-2. eCollection 2019.